In this prospective observational pilot of six patients with refractory chronic migraine, both lidocaine and (R,S)-ketamine infusions produced short-term pain relief but pain had returned to baseline by follow-up, with ketamine giving a slightly larger yet clinically minimal greater reduction. Metabolite analysis showed (2R,6R)-hydroxynorketamine was the predominant ketamine metabolite during most of the infusion.
- Published
- Journal
- Journal of Clinical Pharmacology
- Authors
- Schwenk, E. S., Torjman, M. C., Moaddel, R., Lovett, J., Katz, D., Denk, W., Lauritsen, C., Do, Silberstein, S. D., Wainer, I. W.